The Anti-HER2 Monoclonal Antibody Pertuzumab May Be Effective in Androgen-Independent Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 3, 2003, Pages 143-145

  DeGrendele, Heather ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; NAUSEA; OVARY CANCER; PAIN; PANCREAS ISLET CELL CARCINOMA; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

EID: 0346964519     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70034-8     Document Type: Article

References (10)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26:60-70.
4. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-137.
5. Reese DM, Small EJ, Magrane G, et al. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001; 116:234-239.
6. Calvo BF, Levine AM, Marcos M, et al. Human epidermal growth factor receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9:1087-1097.
7. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92:1918-1925.
8. Mendoza N, Phillips GL, Silva J, et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 2002; 62:5485-5488.
9. Agus D, Gordon M, Taylor C, et al. Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc Am Soc Clin Oncol 2003; 22:192 (Abstract #771).
10. Allison D, Malik M, Qureshi F, et al. Pharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: Phase Ia results. Proc Am Soc Clin Oncol 2003; 22:197 (Abstract #790).